Table 1.
Supratotal resection of glioblastomas (literature review).
| Number of patients | Definition of supratotal resection | Number and rate of supratotal resection cases (%) | OS | PFS | Adjuvant therapy | |
|---|---|---|---|---|---|---|
| Eyüpoglu et al. (61) | 105 | Beyond obvious contrast enhancement using 5-ALA and iMRI | 30 (29%) | 18.5 vs. 14 months (vs. GTR) | NA | RT + TMZ |
| Li et al. (62) | 643 | Resection over 53.21% of FLAIR | 159 (25%) | 20.7 vs. 15.5 months (vs. <53.21% of FLAIR) | NA | NA |
| Esquenazi et al. (63) | 86 | Beyond the zone of enhancement using subpial technique | 25 (29%) | 54 vs. 16.5 months (vs. GTR) | NA | RT + TMZ ± BCNU wafer |
| Grossmann et al. (66) | 103 | ≤ 46% of remnant FLAIR (3 months post operation) | NA | 26.7 vs. 13.4 months (vs. GTR) | NA | RT + TMZ |
| Pessina et al. [65) | 282 | Resection 100% of FLAIR | 21 (7%) | 28.6 ± 5.2 vs. 16.2 ± 1.2 months (vs. GTR) | 24.5 ± 2.4 vs. 11.9 ± 0.6 months (vs. GTR) | TMZ + RT, 6-8 cycles TMZ |
| Glenn et al. (64) | 32 | Removal of at least 1 cm of brain tissue surrounding the enhancement | 7 (21.9%) | 24 vs. 11 months (vs. GTR) | 15 vs. 7 months (vs. GTR) | NA |
OS, overall survival; PFS, progression free survival; GTR, gross total resection; TMZ, temozolomide; RT, radiotherapy; NA, not available; BCNU, carmustine; 5-ALA. aminolevulinic acid; iMRI, intraoperative magnetic resonance imaging; FLAIR, fluid-attenuated inversion recovery; DC, dendritic cell.